BDX

What You Should Know

Becton, Dickinson and Company (BD) is one of the world's largest medical-technology companies, organized into three reporting segments: BD Medical (the largest segment, including syringes and needles, medication-management systems such as the Pyxis automated dispensing platform and the Alaris infusion-pump system, prefillable drug-delivery systems for pharmaceutical partners, and diabetes-care products), BD Life Sciences (specimen-collection products including the iconic Vacutainer blood-collection system, integrated diagnostic instruments and reagents for infectious-disease and other testing, and flow-cytometry and research instruments for the biosciences market), and BD Interventional (surgical and peripheral-intervention products, urology and critical-care products, and the Bard portfolio acquired in 2017 including vascular, oncology, and surgical-specialty devices). Medical-device, diagnostics, and life-sciences-instrument manufacturing is unambiguously permissible at the activity level under standard Sharia methodology — BD's products serve essential healthcare needs. The financial screen consideration is leverage: BD took on substantial debt to fund the 2017 C. R. Bard acquisition and has been deleveraging through free cash flow generation; the consolidated debt-to-market-cap ratio sits in a manageable range that should be verified against the 33% Sharia threshold at the time of investment. Most major Sharia advisory boards classify Becton Dickinson as permissible with purification of small interest-income components.